New Expert Forum for Radiopharmaceuticals: BPI Establishes Working Group to Drive Medical Innovation

The German Association of the Pharmaceutical Industry (BPI) has launched a new working group dedicated to radiopharmaceuticals, creating a specialized forum for manufacturers to address the specific challenges of this highly specialized class of medicinal products. Radiopharmaceuticals are seen as one of the most promising developments in oncology – yet the regulatory environment remains complex and evolving.

“Radiopharmaceuticals represent one of the most dynamic developments in oncology. At the same time, it’s clear that the regulatory framework in this innovative field can be further developed,” said Dr. Kai Joachimsen, Chief Executive of BPI. The new working group will bring together expert knowledge from the industry and contribute this perspective to professional and political dialogue.

The group’s formation follows a year-long preparation process involving key industry players such as Curium, GE Healthcare, Novartis, and Rotop. Magnus Fischer, Senior Manager Public Affairs Radioligand Therapies at Novartis Pharma GmbH, was elected as chair of the working group.

“Manufacturers of radiopharmaceuticals face specific challenges,” explained Fischer. “A structured dialogue with political and regulatory decision-makers at national and European levels is essential. Our goal is to share our experiences and work together on viable solutions that enable medical innovation for the benefit of patients.”

In its initial phase, the working group aims to highlight the regulatory, scientific, and healthcare policy aspects of radiopharmaceuticals, promote constructive exchange, and raise awareness of the unique requirements of this class of drugs.

A thematic day on “Oncology and Radiopharmaceuticals” is already planned for this year, intended to deepen interdisciplinary exchange between industry, science, policy, and regulatory authorities.

With the launch of the Radiopharmaceuticals Working Group, BPI is sending a strong signal for the future of medical innovation and the evolution of regulatory frameworks – all in the interest of improved patient care.